Belite Bio’s IND for LBS-008 gets FDA approval for Phase 1 trial
Category: #health  By Mateen Dalal  Date: 2019-04-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Belite Bio’s IND for LBS-008 gets FDA approval for Phase 1 trial

Drug development company, Belite Bio’s Investigational New Drug application for LBS-008 (BPN-14967), developed to treat AMD and Stargardt disease, has reportedly been approved by the U.S. Food and Drug Administration. 

As per trusted sources, Belite Bio’s new drug is the first to graduate from the US National Institute of Health’s Blueprint Neurotherapeutics Network, which has invested toward LBS-008's discovery and development and will continue to offer support and investment until the conclusion of its Phase 1 clinical trial. 

Dr. Konstantin Petrukhin, Columbia University Medical Center’s Associate Professor of Ophthalmic Science and inventor of the technology stated that the commencement of the Phase 1 trial is a significant milestone for LBS-008, which was sponsored by the NIH Blueprint Program right from lead optimization to preclinical proof of concept. The drug is anticipated to bring hope to a lot of patients affected by incurable forms of macular degeneration, Dr. Petrukhin added.

Dr. Tom Lin, Chairman of Belite Bio, said in a statement that the company is thrilled to announce the start of Phase 1 clinical trial of LBS-008 in the US in conjunction with the NIH.

The current favorable regulatory view of its technology has encouraged the company, as well as the systematic analysis published by the UK National Institute for Health Research, recognizing reduction of RBP4 as the most lucrative treatments for dry AMD and Stargardt disease, added Dr. Lin.

The company plans to continue working closely with its collaborators until the next clinical and regulatory milestone, Dr. Lin said.

For the record, LBS-008 is a treatment dedicated to preventing toxin build up in the eye that leads to severe conditions like atrophic dry AMD and Stargardt disease. The drug development company Belite Bio owns exclusive global rights for LBS-008. The drug had received orphan drug designation (ODD) in the US & EU, and a rare pediatric disease designation from the FDA for treating patients with Stargardt disease, reported sources.  

Source Credits: https://www.biospace.com/article/releases/belite-bio-announces-fda-approval-of-investigational-new-drug-ind-for-phase-1-clinical-trial-of-lbs-008-to-treat-macular-degeneration-and-stargardt-disease/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...